1. Home
  2. GPN vs NTRA Comparison

GPN vs NTRA Comparison

Compare GPN & NTRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

GPN

Global Payments Inc.

HOLD

Current Price

$78.91

Market Cap

17.2B

ML Signal

HOLD

Logo Natera Inc.

NTRA

Natera Inc.

HOLD

Current Price

$244.52

Market Cap

27.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GPN
NTRA
Founded
1967
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Business Services
Medical Specialities
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
17.2B
27.0B
IPO Year
2001
2015

Fundamental Metrics

Financial Performance
Metric
GPN
NTRA
Price
$78.91
$244.52
Analyst Decision
Buy
Strong Buy
Analyst Count
22
16
Target Price
$103.20
$227.69
AVG Volume (30 Days)
2.1M
1.7M
Earning Date
11-04-2025
11-06-2025
Dividend Yield
1.27%
N/A
EPS Growth
34.30
N/A
EPS
7.12
N/A
Revenue
$10,076,185,000.00
$2,116,676,000.00
Revenue This Year
N/A
$32.77
Revenue Next Year
$4.44
$16.51
P/E Ratio
$11.85
N/A
Revenue Growth
22.33
38.17
52 Week Low
$65.93
$125.38
52 Week High
$118.86
$245.59

Technical Indicators

Market Signals
Indicator
GPN
NTRA
Relative Strength Index (RSI) 54.48 80.03
Support Level $74.72 $233.67
Resistance Level $80.78 $240.18
Average True Range (ATR) 1.97 7.39
MACD 1.07 0.68
Stochastic Oscillator 78.72 97.49

Price Performance

Historical Comparison
GPN
NTRA

About GPN Global Payments Inc.

Global Payments is a leading provider of payment processing and software solutions and focuses on serving small and midsize merchants. The company operates in 30 countries and generates about one fourth of its revenue from outside North America, primarily in Europe and Asia. In 2019, Global Payments merged with Total System Services in an all-stock deal that gave Total System Services shareholders 48% of the combined company's shares. The merger added issuer processing operations.

About NTRA Natera Inc.

Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.

Share on Social Networks: